https://www.selleckchem.com/products/osmi-1.html
The combination of BRAF and MEK inhibitors represents the standard of care treatment for patients with metastatic -mutated melanoma, notwithstanding the high frequency of emergent resistance. Moreover, therapeutic options outside clinical trials are scarce when patients have progressed after both targeted therapy and therapy with immune checkpoint inhibitors. In this article, we report our experience with targeted therapy rechallenging with BRAF and MEK inhibitors in patients with metastatic -mutated melanoma after progression with kinas
Like
Comment
Share
